Related Experiment Videos
[Treatment of pertussis with cefoperazone (author's transl)]
Insights
Cefoperazone (CPZ) effectively treated pertussis in 15 patients, showing excellent or good clinical responses. This antibiotic demonstrated potent activity against Bordetella pertussis with no observed adverse effects on liver or kidney function.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Background:
- Pertussis, a highly contagious respiratory infection, poses significant health risks, particularly in pediatric populations.
- Antibiotic resistance in Bordetella pertussis necessitates the evaluation of alternative treatment options.
- Cefoperazone (CPZ) is a third-generation cephalosporin with broad-spectrum antibacterial activity.
Purpose of the Study:
- To evaluate the efficacy and safety of cefoperazone (CPZ) in the treatment of pertussis.
- To determine the in vitro activity of CPZ against Bordetella pertussis strains.
- To assess the impact of CPZ treatment on hepatic and renal function in pertussis patients.
Main Methods:
- A clinical trial involving 15 patients diagnosed with pertussis.
- Intravenous administration of cefoperazone (CPZ) at a dosage of 100-200 mg/kg/day.
- In vitro susceptibility testing of 17 Bordetella pertussis strains against CPZ.
Main Results:
- Cefoperazone (CPZ) exhibited potent in vitro activity against Bordetella pertussis, with Minimum Inhibitory Concentrations (MICs) below 0.006 mcg/ml, comparable to PIPC.
- No adverse effects on hepatic or renal function were observed during the treatment period.
- Excellent clinical response was achieved in 13 patients (86.7%), and good response in 2 patients (13.3%).
Conclusions:
- Cefoperazone (CPZ) is a safe and effective therapeutic option for pertussis treatment.
- CPZ demonstrates significant in vitro efficacy against Bordetella pertussis.
- Further clinical studies are warranted to establish CPZ as a standard treatment for pertussis.
Abstract:
Clinical trial of cefoperazone (CPZ) for the treatment of 15 cases suffering from pertussis was performed and the results were as follows. The method of administration, as a rule intravenous infusion was performed at 100 approximately 200 mg/kg/day. (1) Seventeen strains of Bordetella pertussis showed under 0.006 mcg/ml of MIC. It was similar to PIPC. (2) Any effect to hepatic or renal function was not observed. (3) Clinical response obtained in these cases was excellent in 13 cases (86.7%), good in 2 cases (13.3%) and none of poor case.